Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

Completed · Phase 3

Conditions studied: Hyperemia

In brief

To compare the efficacy and safety of brimonidine tartrate ophthalmic solution 0.025% with its vehicle for the treatment of ocular redness in a population of adult and geriatric participants with ocular redness.

Key facts

Study ID

NCT01959230

Run by

Bausch & Lomb Incorporated

People needed

60

Starts

2013-11-07

Expected to finish

2013-12-20

Last updated by the study team

2019-10-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years of age.
• Have a history of redness relief drops use or expressed a desire to use drops for redness relief, within the last 6 months.
• Have ocular health within normal limits including a calculated best-corrected visual acuity of 0.3 logarithm of the minimum angle of resolution (logMAR) or better in each eye, as measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart.

You may not qualify if…

• Any ocular/systemic health problems.
• Use of any disallowed medications.

Where it is running

• Bausch & Lomb Incorporated — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.